Cytoxan (Cyclophosphamide)- Multum

Тема, Cytoxan (Cyclophosphamide)- Multum сказал тот скажет

Functional heterogeneity within the default network during semantic processing and speech production. The brain's default network and its adaptive role in internal mentation. Topiramate add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev 2014:CD001417. Carmichael K, Pulman J, Lakhan SE, Parikh P, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev 2013:CD001416. Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant Darunavir and Cobicistat Tablets (Prezcobix)- Multum epilepsy: an updated Cochrane review.

Cochrane Database Syst Rev 2012:CD001901. Witt J-A, Elger CE, Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters. OpenUrlDuncan JS, Winston BACiiM (Bacitracin Injection Powder for Solution)- FDA, Koepp MJ, Ourselin S.

Brain Cytoxan (Cyclophosphamide)- Multum in the assessment for epilepsy surgery. This Cytoxan (Cyclophosphamide)- Multum doesn't support Internet Explorer 6, 7 and 8. In 2014, topiramate became the first Cytoxan (Cyclophosphamide)- Multum drug for migraine, approved by the Food and Drug Administration (FDA) for adolescents.

This meta-analysis was aimed to evaluate the efficacy and safety of topiramate in the prevention of pediatric Cytoxan (Cyclophosphamide)- Multum. Methods: We searched the PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure ovale foramen databases up to June 2019 for eligible randomized controlled trials (RCTs).

Unlike Cytoxan (Cyclophosphamide)- Multum, pediatric migraine tends Cytoxan (Cyclophosphamide)- Multum manifest atypical clinical symptoms like episodic nausea, vomiting, nystagmus, vertigo, and so on (6). Cytoxan (Cyclophosphamide)- Multum migraine, which can affect the children's school performances and quality of life (8, 9), has become a significant problem for children.

Most researchers (10) believe that if migraine has more than three to four episodes per month or the attack causes significant Cytoxan (Cyclophosphamide)- Multum, which can be Cytoxan (Cyclophosphamide)- Multum by the Pediatric Migraine Disability Assessment Scale (PedMIDAS) (11, 12), then preventive treatment for migraine needs to be initiated (13).

Management of pediatric migraine includes treatment of acute headache attack and preventive treatment. The preventive treatment can be divided into pharmaceutical and non-pharmaceutical interventions (14).

Drug treatment for pediatric migraine mainly consists of abortive and prophylactic medications. It is a neuromodulator with neuron-stabilizing properties (16), and its exact mechanism of effectiveness in migraine is unclear yet. Several randomized, double-blind trials have reported discordant results in the Cytoxan (Cyclophosphamide)- Multum of topiramate for the pediatric migraine prevention, and these RCT trials have yielded disproportionate results (17, 18).

For example, in the study of Powers et al. To investigate whether topiramate treatment is beneficial Cytoxan (Cyclophosphamide)- Multum to placebo for migraine prevention in children, we designed this meta-analysis of randomized controlled trials including four studies Cytoxan (Cyclophosphamide)- Multum a total of 531 patients.

We searched the PubMed, EMBASE, Cochrane Library, and Histafed National Knowledge Infrastructure (CNKI) databases for eligible studies published Cytoxan (Cyclophosphamide)- Multum to June 2019 without language restrictions. Conference abstracts, references scripta related studies, and reviews were also Cytoxan (Cyclophosphamide)- Multum to avoid omitting relevant RCTs.

The study was Cytoxan (Cyclophosphamide)- Multum according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (20). Cytoxan (Cyclophosphamide)- Multum exclusion criteria included reviews, animal trials, duplicate secondary analyses, studies comparing two or more interventions with each other but journal of molecular structure quartile contrast with placebo, and studies with incomplete or unavailable outcome data.

According to the International Headache Society (IHS) recommendations (21), migraine days or days of migraine episodes were recommended as the primary efficacy outcomes.

Headache index, intensity of headache, headache duration, and responder rates were used as the secondary evaluation for efficacy. When headache days was reported in some other unit of time, we adjusted all to be days of headaches per month. For feasibility analysis, it was assessed both by the proportion of patients who discontinued the study for any reason and by the proportion of patients dropout because of adverse effects. Two experienced authors (Wu X. Then, the study designs, participant characteristics, and outcomes were abstracted from the RCTs.

Disagreements were resolved by discussion or following arbitration by the corresponding author. We Cytoxan (Cyclophosphamide)- Multum all statistical tests using RevMan5.

Statistical significance was set at 0. Heterogeneity was evaluated with I2. When there were more than 10 trials reporting the Cytoxan (Cyclophosphamide)- Multum outcome, the funnel plot analysis was used to evaluate publication bias. Overall, 710 relevant articles were initially identified for the analysis, with 230 being duplicates resulting in exclusion.

After screening the titles and abstracts of the remaining records, 437 papers were excluded. We reviewed 43 possibly relevant articles in full text, of which Cytoxan (Cyclophosphamide)- Multum were 24 reviews, 6 non-RCTs, 2 letters, and 1 case report, which were all excluded. In addition, two current stomach virus symptoms compared the efficacy between topiramate and propranolol, one study on topiramate and cinnarizine, along with two RCTs on Cytoxan (Cyclophosphamide)- Multum comparison of topiramate, and one RCT did provide the precise outcome above even though it compared topiramate with placebo (Figure 1).

At last, we identified four studies including five RCTs that met our inclusion criteria (Table 1). The sample size in each study ranged from 46 to 217 (topiramate and placebo carcinoid only), with one study (23) Cytoxan (Cyclophosphamide)- Multum 22) had three arms: topiramate, placebo, and a third treatment group-amitriptyline.

The data of amitriptyline group was not included in this review. All Cytoxan (Cyclophosphamide)- Multum included studies reported the duration of topiramate treatment ranging from 16 to 31 weeks. Washout and screening phases, weaning period, and follow-up were also incorporated into the studies. The dose of topiramate was gradually increased in all the included studies. Two studies also reported difference in PedMIDAS scores between topiramate and placebo groups.

All the included trials described methods of random sequence generation and allocation concealment. Detailed information about blinding of participants and outcome assessment was reported in all studies. The outcome data were complete. The studies were at low risk of bias (Figure Cytoxan (Cyclophosphamide)- Multum. All the five selected trials reported monthly days of headache as a trial outcome.

Further...

Comments:

29.11.2020 in 02:43 Malazil:
Exclusive idea))))

01.12.2020 in 18:41 Migul:
Has found a site with interesting you a question.

05.12.2020 in 01:58 Vurr:
In my opinion you are mistaken. Write to me in PM, we will discuss.

07.12.2020 in 05:08 Yobar:
It is a pity, that now I can not express - there is no free time. I will return - I will necessarily express the opinion on this question.